Celldex Announces Upcoming Data Presentations At The Society For Neuro-Oncology 17th Annual Scientific Meeting And Education Day

Celldex Therapeutics, Inc. (NASDAQ: CLDX) today announced upcoming data presentations at the Society of Neuro-Oncology’s 17 th Annual Scientific Meeting and Education Day to be held in Washington, DC from November 15 through November 19, 2012. Duane A. Mitchell, MD, PhD, Assistant Professor of Surgery (Neurosurgery), Duke University Medical Center will present updated overall survival data from the rindopepimut Phase 2 ACT III, ACT II and ACTIVATE studies in an educational session entitled “Immunotherapy of Malignant Brain Tumors” to be held from 11:10-11:30 am ET on Thursday, November 15, 2012. Michael Weller, MD, Professor, Department of Neurology, University Hospital Zurich will present data from a cohort of patients with EGFRvIII-positive glioblastoma that were included in the Phase 3 Radiation Therapy Oncology Group’s (RTOG) 0525 study (closed to accrual in 2008) in an educational session called “Biomarkers and Clinical Care: are we there yet?” to be held from 5:05 to 5:25 pm ET on Thursday, November 15, 2012. This analysis will provide a more contemporary historical control dataset on expected outcomes for patients with EGFRvIII-positive disease.

Rindopepimut is an investigational immunotherapeutic vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII). EGFRvIII is a mutated form of the epidermal growth factor receptor (EGFR) that is only expressed in cancer cells and not in normal tissue and is a transforming oncogene that can directly contribute to cancer cell growth. Expression of EGFRvIII is linked to poor long term survival regardless of other factors such as extent of resection and age. EGFRvIII is expressed in approximately 30% of glioblastoma tumors. Celldex is actively enrolling two clinical studies of rindopepimut—a Phase 3 international study called ACT IV in patients with newly diagnosed EGFRvIII-positive glioblastoma and a Phase 2 study called ReACT in patients with recurrent EGFRvIII-positive glioblastoma. Dr. Mitchell has a patent that has been licensed by Celldex and may receive royalties related to sales of this immunotherapeutic vaccine.

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today